Race Oncology Limited
Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company's lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need… Read more
Race Oncology Limited (RAONF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.076x
Based on the latest financial reports, Race Oncology Limited (RAONF) has a cash flow conversion efficiency ratio of -0.076x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.39 Million) by net assets ($18.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Race Oncology Limited - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Race Oncology Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Race Oncology Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Race Oncology Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Teamlease Services Limited
NSE:TEAMLEASE
|
0.046x |
|
DHAWF
PINK:DHAWF
|
N/A |
|
Zhejiang Huaye Plastics Machinery Co., Ltd.
SHE:301616
|
0.025x |
|
Fuzul Gayrimenkul Yatirim Ortakligi Anonim Sirketi
IS:FZLGY
|
0.064x |
|
HIGHPEAK ENERGY DL-0001
F:58R
|
N/A |
|
Euroapi S.A
PINK:EAPIF
|
0.019x |
|
Selcuk Ecza Deposu Ticaret ve Sanayi AS
IS:SELEC
|
-0.012x |
|
Harum Energy Tbk PT
JK:HRUM
|
-0.062x |
Annual Cash Flow Conversion Efficiency for Race Oncology Limited (2013–2024)
The table below shows the annual cash flow conversion efficiency of Race Oncology Limited from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | $18.31 Million | $-9.55 Million | -0.521x | -24.73% |
| 2023-06-30 | $25.49 Million | $-10.65 Million | -0.418x | -141.15% |
| 2022-06-30 | $36.11 Million | $-6.26 Million | -0.173x | +49.37% |
| 2021-06-30 | $13.72 Million | $-4.70 Million | -0.342x | +20.92% |
| 2020-06-30 | $5.69 Million | $-2.46 Million | -0.433x | +18.25% |
| 2019-06-30 | $5.05 Million | $-2.67 Million | -0.530x | -8.53% |
| 2018-06-30 | $7.93 Million | $-3.87 Million | -0.488x | -11.53% |
| 2017-06-30 | $5.64 Million | $-2.47 Million | -0.437x | -482.87% |
| 2016-06-30 | $4.08 Million | $-306.06K | -0.075x | +99.59% |
| 2015-06-30 | $5.69K | $-103.69K | -18.233x | -3337.39% |
| 2014-06-30 | $-70.24K | $-39.56K | 0.563x | +2869.35% |
| 2013-06-30 | $93.38K | $-1.90K | -0.020x | -- |